Christopher M Carosino

4PUBLICATIONS
58CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 20, 2026
An Integrin β6-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer.

|Apr 28, 2025
PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors.

Sherif Abdelhamed, Xinqun Zhang, Weiping Zeng

|Oct 28, 2024
Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47.

Matthew R Levengood, Christopher M Carosino, Xinqun Zhang

|May 01, 2024
The Vedotin Antibody-Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles.

Haley D Neff-LaFord, Sarah A Carratt, Christopher Carosino

Pageof 1

Frequent Collaborators

3 joint publications

Matthew R Levengood

2 joint publications

Haley D Neff-LaFord

2 joint publications

Devra J Olson

2 joint publications

Shyra J Gardai